In vivo最新文献

{"title":"First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of ¹⁰BPA.","authors":"Hironobu Yanagie, Syoji Maruyama, Kazuyuki Oyama, Yasuo Ono, Shinichi Kuroyama, Yasumasa Nonaka, Ryo Hatae, Yoshitaka Furuya, Minoru Suzuki, Shin-Ichiro Masunaga, Yoshinori Sakurai, Natsuko Kondo, Hiroki Tanaka, Akira Maruhashi, Koji Ono, Takumichi Sugihara, Hiroyuki Takahashi","doi":"10.21873/invivo.13948","DOIUrl":"https://doi.org/10.21873/invivo.13948","url":null,"abstract":"<p><strong>Background/aim: </strong>Boron neutron capture therapy (BNCT) is a novel treatment that induces targeted tumor cell damage through the selective accumulation of ¹⁰B compounds in cancer cells followed by the production of alpha and lithium particles using thermal neutron irradiation. Despite its potential, clinical applications of BNCT for recurrent gastrointestinal cancers remain limited. This study presents the first pilot clinical evaluation of BNCT using intravenous boronophenylalanine (¹⁰BPA) for such cancers.</p><p><strong>Case reports: </strong>Four patients with recurrent gastrointestinal cancers were enrolled in this phase I-II clinical study. All had tumors refractory to standard treatments, including surgery, chemotherapy, and radiotherapy. BNCT was performed using thermal neutron irradiation at Kyoto University Research Reactor. ¹⁰BPA was administered intravenously at 400 mg/kg, and no severe adverse effects were observed. Tumor responses varied, with one patient achieving partial response and three demonstrating stable disease at three months post-treatment. Notably, BNCT alleviated cancer-related symptoms, such as pain and nerve compression, improving patients' quality of life. Dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues.</p><p><strong>Conclusion: </strong>BNCT is a promising modality for recurrent gastrointestinal cancers, offering symptom relief and potential antitumor effects. Its safety and feasibility were demonstrated in this study. Future research should explore fractionated BNCT and combination therapies with immunotherapy or targeted agents to enhance efficacy further.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1470-1491"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma.","authors":"Nobuki Furubayashi, Manabu Mochida, Atsuhiro Kijima, Yushi Fujimoto, Motonobu Nakamura, Takahito Negishi","doi":"10.21873/invivo.13961","DOIUrl":"https://doi.org/10.21873/invivo.13961","url":null,"abstract":"<p><strong>Background/aim: </strong>The impact of steroid premedication on the efficacy and cutaneous toxicity of enfortumab vedotin (EV) in advanced urothelial carcinoma (UC) is unclear.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to November 2024.</p><p><strong>Results: </strong>Twenty-eight patients (male, n=16; median age, 71 years) were enrolled. Dexamethasone 6.6 mg was administered intravenously prior to EV in six (21.4%) patients. There were no differences in the overall response and disease control rates between patients with and without steroid premedication (<i>p</i>=0.653 and <i>p</i>>0.99, respectively). The progression-free survival was not significantly associated with or without steroid premedication (not estimable <i>vs.</i> 4.3 months, <i>p</i>=0.501). There were no marked differences in the incidence of all grades of EV-related cutaneous adverse events (AEs) between patients with and without steroid premedication (33.3% <i>vs.</i> 45.5%, <i>p</i>=0.673). There was no significant difference in the incidence of grade ≥3 EV-related cutaneous AEs between the patients with and without steroid premedication (16.7% <i>vs.</i> 36.4%, <i>p</i>=0.630). Multivariate analysis revealed that a performance status ≥2 was an independent prognostic factor for progression-free survival (hazard ratio=4.653, 95% confidence interval=1.263-17.140, <i>p</i>=0.021), and steroid premedication was not (<i>p</i> =0.869).</p><p><strong>Conclusion: </strong>In EV treatment, steroid premedication did not affect clinical outcomes. The incidence and severity of EV-related cutaneous toxicity tended to improve in patients who received steroid premedication, although no significant differences were observed.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1607-1614"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Lipophosphonoxin-loaded Polycaprolactone Nanofiber Dressing for Full-thickness Wounds in a Porcine Model.","authors":"Hubert Šuca, Štefan Juhás, Jana Juhásová, Věra Jenčová, Eva Kuželová Košťáková, David Lukáš, Peter Bohuš, Zuzana Ballová, Robert Zajíček, Dominik Rejman, Peter Gál","doi":"10.21873/invivo.13937","DOIUrl":"https://doi.org/10.21873/invivo.13937","url":null,"abstract":"<p><strong>Background/aim: </strong>This study investigated the therapeutic potential of lipophosphonoxin (LPPO), an antibacterial agent, loaded into polycaprolactone nanofiber dressings (NANO-LPPO) for full-thickness wound healing. Using a porcine model, we aimed to assess the impact of areal weight of the dressing (10, 20 and 30 g/m²) on wound-healing outcomes and validate findings from previous murine studies.</p><p><strong>Materials and methods: </strong>Full-thickness wounds were created on porcine skin and treated with the NANO-LPPO dressings of differing thickness. Positive control (Aquacel Ag+) and standard control (Jelonet) groups were included for comparison. Wound-healing progression was evaluated macroscopically and on the histological level.</p><p><strong>Results: </strong>Macroscopic observations indicated no signs of infection in any group, with wounds covered by scabs by day 14. Thicker dressings (areal weights of 30 and 20 g/m²) demonstrated superior performance in promoting the formation of granulation tissue and healing compared to the thinner version (areal weight of 10 g/m²). LPPO-loading enhanced scaffold wettability and biodegradability without impairing healing outcomes. Both control groups exhibited similar healing characteristics.</p><p><strong>Conclusion: </strong>The findings underscore the importance of optimizing dressing thickness for effective wound healing. NANO-LPPO dressings exhibit translational potential as a therapeutic option for full-thickness wounds, warranting further preclinical and regulatory evaluation to support clinical application.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1331-1340"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Chemopreventive and Antioxidant Effects of Spearmint Leaf Hydroethanolic Extract in HPV16-transgenic Mice.","authors":"Tiago M Jesus, Tiago Azevedo, Rita Silva-Reis, Tiago Ferreira, Elisabete Nascimento-Gonçalves, Catarina Medeiros, João Ferreira, Adelina Gama, Isabel Gaivão, Maria João Pires, Germano Lanzarin, Luís Félix, Carlos Venâncio, Rui Medeiros, Margarida M S M Bastos, Tiane C Finimundy, Lillian Barros, Rui M Gil DA Costa, Paula A Oliveira","doi":"10.21873/invivo.13934","DOIUrl":"https://doi.org/10.21873/invivo.13934","url":null,"abstract":"<p><strong>Background/aim: </strong>Human papillomavirus (HPV) is the most common sexually transmitted infectious agent and, in cases of persistent infection, may cause cancer. This study evaluated the toxicological and antitumor properties of <i>Mentha spicata</i> extract (MSE) in KP14HPV16 mice, which carry HPV16 oncogenes.</p><p><strong>Materials and methods: </strong>Thirty-three female FVB/n mice (<i>Mus musculus</i>), including 17 HPV-transgenic and 16 wild-type (WT) mice, were divided into six groups. The control groups received tap water (WT-C, <i>n</i>=5, and HPV-C, <i>n</i>=6), while the treatment groups received either 0.50 mg/ml MSE (WT-50 and HPV-50, <i>n</i>=6) or 0.55 mg/ml MSE (WT-55 and HPV-55, <i>n</i>=5) in drinking water for 28 days. Afterwards, animals were sacrificed, and blood and organs were collected for histopathological and biochemical analysis.</p><p><strong>Results: </strong>The main phenolic compounds in MSE were rosmarinic acid and luteolin-<i>O</i>-glucoronide. MSE did not significantly affect weight gain in WT mice; however, WT-55 gained significantly more weight than HPV-55. MSE demonstrated antioxidant activity as indicated by the modulation of hepatic superoxide dismutase and glutathione S-transferase (GST) activity, as well as renal GST activity, in MSE-treated HPV groups. MSE did not reduce histological lesion incidence or systemic inflammation in HPV16-transgenic mice.</p><p><strong>Conclusion: </strong>In general, while MSE was safe and exhibited antioxidant activity, it did not significantly impact HPV16-induced lesions, warranting further research to assess systemic effects with different concentrations and durations.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1303-1313"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Matrix Metalloproteinase-7 Genotypes With Nasopharyngeal Carcinoma Risk.","authors":"Liang-Chun Shih, Shih-Wei Hsu, Kai-Yuan Chen, Che-Lun Hsu, Yen-Fang Liu, Yun-Chi Wang, Hou-Yu Shih, Wen-Shin Chang, DA-Tian Bau, Chia-Wen Tsai","doi":"10.21873/invivo.13935","DOIUrl":"https://doi.org/10.21873/invivo.13935","url":null,"abstract":"<p><strong>Background/aim: </strong>Nasopharyngeal carcinoma (NPC) is a multifactorial malignancy influenced by Epstein-Barr virus (EBV) infection, genetic susceptibility, and environmental factors. Matrix metalloproteinase-7 (MMP-7), a key regulator of extracellular matrix remodeling, has been implicated in NPC progression. This study investigated the association between <i>MMP-7</i> rs11568818 and rs11568819 genotypes and NPC susceptibility in a Taiwanese cohort consisted of 208 NPC cases and 416 cancer-free controls.</p><p><strong>Materials and methods: </strong>The genotypic patterns of <i>MMP-7</i> rs11568818 and rs11568819 were revealed by utilizing PCR-RFLP methodology. In addition, the interaction between <i>MMP-7</i> genotypes and lifestyle factors (including smoking, alcohol consumption, and betel quid chewing) was also analyzed in a stratified manner.</p><p><strong>Results: </strong>Genotypic distribution analysis of <i>MMP-7</i> rs11568818 showed no significant association with NPC risk (<i>p</i> for trend=0.4641). Individuals carrying the AG (OR=1.22, 95%CI=0.79-1.90, <i>p</i>=0.4384) or GG (OR=1.74, 95%CI=0.52-5.79, <i>p</i>=0.5539) genotypes exhibited a modestly elevated, but statistically non-significant, risk compared to AA carriers. Similarly, allelic frequency analysis indicated that the G allele did not significantly contribute to NPC susceptibility (OR=1.28, 95%CI=0.87-1.87, <i>p</i>=0.2433). Stratified analysis revealed a significant interaction between <i>MMP-7</i> rs11568818 and smoking status (<i>p</i> for trend=0.0018). Among smokers, AG and GG genotypes were associated with an increased NPC risk (AG: OR=2.70, 95%CI=1.34-5.44, <i>p</i>=0.0076; GG: OR=9.27, 95%CI=1.01-84.66, <i>p</i>=0.0345), which remained significant after adjusting for confounders (adjusted OR=2.53, 95%CI=1.27-4.88; adjusted OR=7.89, 95%CI=1.02-47.38). No interactions were observed with alcohol consumption or betel quid chewing. Additionally, no polymorphic genotypes were detected for <i>MMP-7</i> rs11568819 in the studied population.</p><p><strong>Conclusion: </strong>While <i>MMP-7</i> rs11568818 does not directly influence NPC susceptibility in a Taiwanese population, its interaction with smoking may contribute to elevated NPC risk.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1314-1324"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.","authors":"Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Sosuke Yamamoto, Kiyoko Shimada, Keisuke Kazama, Ayako Tamagawa, Mie Tanabe, Keisuke Komori, Natsumi Kamiya, Naoko Okuda, Koji Numata, Mamoru Uchiyama, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.13952","DOIUrl":"https://doi.org/10.21873/invivo.13952","url":null,"abstract":"<p><strong>Background/aim: </strong>Body composition changes and nutritional status affect the oncological outcomes in various malignancies. Modified advanced lung cancer inflammation index (mALI) evaluates both body composition changes and nutritional status. Herein, we aimed to examine the potential of mALI as a biomarker for gastric cancer (GC).</p><p><strong>Patients and methods: </strong>The medical records of 327 consecutive patients with gastric cancer who underwent curative resection at Yokohama City University from 2015 to 2022 were retrospectively reviewed. mALI was defined follows: Appendicular skeletal muscle index×Serum albumin/Neutrophil-to-lymphocyte ratio. The clinical impact of the mALI on the short- and long-term oncological outcomes was evaluated using Kaplan-Meier curves and Cox's proportional hazards models.</p><p><strong>Results: </strong>The 327 patients were classified into the mALI-low (n=121) and mALI-high (n=206) groups, respectively. The 1-, 3-, and 5-year overall survival (OS) rates were 94.0%, 71.4%, and 59.2%, respectively, in the mALI-low group, and 95.5%, 85.0%, and 79.9%, in the mALI-high group. In the multivariable analysis for OS, the mALI was identified as an independent prognostic factor [hazard ratio (HR)=1.794; 95% confidence interval (CI)=1.155-2.786, <i>p</i>=0.009]. The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 79.6%, 66.0%, and 54.3%, respectively, in the mALI-low group, and 90.7%, 79.1%, and 75.5% in the mALI-high group. The multivariable analysis of RFS, identified the mALI as an independent prognostic factor (HR=1.654; 95% CI=1.105-2.477, <i>p</i>=0.015). In addition, the mALI status affected short-term oncological outcomes, including the occurrence of postoperative surgical complications and the introduction of postoperative adjuvant chemotherapy.</p><p><strong>Conclusion: </strong>The mALI was an independent prognostic factor for OS and RFS in patients with GC. Our results suggest that the mALI is a promising biomarker for GC and a useful tool for the treatment and management of GC.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1524-1532"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Different Sandblasting Parameters on the Properties of Additively Manufactured and Machined Titanium Surfaces.","authors":"Osman Akbas, Leif Reck, Anne Jahn, Jörg Hermsdorf, Meike Stiesch, Andreas Greuling","doi":"10.21873/invivo.13979","DOIUrl":"https://doi.org/10.21873/invivo.13979","url":null,"abstract":"<p><strong>Background/aim: </strong>In dentistry, the surfaces of titanium implants are often sandblasted and acid-etched in order to support successful osseointegration. The aim of this study was to investigate the impact of various sandblasting parameters on the surface roughness, contact angle and surface energy of additively manufactured (TiAl6V4) and machined commercially pure titanium (cpTi) surfaces.</p><p><strong>Materials and methods: </strong>A total of 56 disc-shaped samples were produced using either laser powder bed fusion (TiAl6V4) or using precision cutting (cpTi). The samples were then sandblasted with different angles, distances, and pressures using an automated sandblasting machine. Afterwards, surface roughness and contact angle for water and diiodomethane were measured, and scanning electron microscopy images were taken.</p><p><strong>Results: </strong>The results showed that the initially rough TiAl6V4 samples became smoother after sandblasting, while the smooth cpTi surfaces became rougher. Sandblasting pressure had the most significant influence on surface roughness. The surface energy of sandblasted TiAl6V4 samples showed no significant change compared to the as-built state (26.6±1.3 to 26.3±1.8 mJ/m²). In contrast, cpTi samples showed a reduction in surface energy after sandblasting (32.3±1.6 to 26.8±1.2 mJ/m²). Scanning electron microscopy revealed irregular surfaces with grooves and ridges for both types of samples. The roughness of TiAl6V4 decreased at higher sandblasting pressures, whereas cpTi surfaces became rougher.</p><p><strong>Conclusion: </strong>Surface roughness after sandblasting is strongly influenced by the initial surface, which differs in additively manufactured TiAl6V4 samples compared to machined cpTi surfaces.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1767-1785"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102.","authors":"Toshifumi Yamaguchi, Motoki Yoshida, Koichi Taira, Shinya Tokunaga, Takeshi Kato, Masato Nakamura, Naotoshi Sugimoto, Soichi Fumita, Masayoshi Yasui, Yasuhiro Miyake, Hisato Kawakami, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh","doi":"10.21873/invivo.13950","DOIUrl":"https://doi.org/10.21873/invivo.13950","url":null,"abstract":"<p><strong>Background/aim: </strong>The combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety and efficacy of this regimen in Japanese patients have not been sufficiently investigated.</p><p><strong>Patients and methods: </strong>This phase II study included patients aged ≥76 years or those aged 65-75 years who were unsuitable for intensive chemotherapy. Capecitabine at 2000 mg/m²/day (days 1-14) plus bevacizumab at 7.5 mg/kg (day 1) were administered every 3 weeks. The primary endpoint was progression-free survival. Secondary endpoints included overall survival, response rate, disease control rate, and toxicities.</p><p><strong>Results: </strong>Thirty-six patients were enrolled between July 2011 and July 2014, of whom 33 were included in the analysis. The median patient age was 78 years (range=67-86 years). A total of 28 patients had a performance status of 0 or 1, and five of 2. The median progression-free and overall survival were 10.3 (95% confidence interval=9.2-15.4) and 27.9 (95% confidence interval=24.2-50.1) months, respectively. The response and disease control rates were 30.3% and 91.0%, respectively. The major grade 3 or 4 toxicities were hypertension (n=12, 36%) and hand-foot syndrome (n=4, 12%). One patient experienced a grade 4 gastrointestinal perforation.</p><p><strong>Conclusion: </strong>The combination of capecitabine and bevacizumab demonstrated favorable efficacy and tolerability in Japanese patients with metastatic colorectal cancer who were unsuitable for intensive chemotherapy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1505-1513"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Mike Barbeck","doi":"10.21873/invivo.13976","DOIUrl":"https://doi.org/10.21873/invivo.13976","url":null,"abstract":"","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1739"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlling Cellular Behavior by Surface Design of Titanium-based Biomaterials.","authors":"Tonya Andreeva, Osman Akbas, Anne Jahn, Andreas Greuling, Andreas Winkel, Meike Stiesch, Rumen Krastev","doi":"10.21873/invivo.13980","DOIUrl":"https://doi.org/10.21873/invivo.13980","url":null,"abstract":"<p><strong>Background/aim: </strong>Titanium alloys, especially Ti₆Al₄V, are widely used in orthopedic and dental implants. Additive manufacturing has emerged as an innovative fabrication technique for titanium implants, gradually replacing traditional machining methods. A notable feature of additively manufactured medical devices is their considerable surface heterogeneity and roughness. Coating these materials to achieve physical and chemical uniformity is essential for enhancing biocompatibility. This study evaluates the combined effect of surface roughness (ranging from sub-micrometer to micrometer scale) and three nanometer-thick polyelectrolyte multilayer coatings on protein adsorption, as well as the adhesion and proliferation of normal human osteoblasts.</p><p><strong>Materials and methods: </strong>The adhesion of human osteoblasts to various substrates (either uncoated or coated) was quantified using a lactate dehydrogenase assay and scanning electron microscopy. The surface density of adsorbed human serum albumin was analyzed by the Bradford assay.</p><p><strong>Results: </strong>Application of polyelectrolyte multilayer coatings significantly increased the hydrophilicity of titanium substrates without altering their sub-micrometer and micrometer roughness or topography. The coatings rich in reactive amino groups were found to enhance the adsorption of human serum albumin and promote the adhesion of osteoblasts.</p><p><strong>Conclusion: </strong>The chemical composition of the surface, particularly the presence of free primary amino groups, significantly affects cellular behavior in machined, sand-blasted, and additively manufactured titanium materials, while the impact of surface roughness appears secondary. No correlation was observed between surface hydrophilicity and protein adsorption or cell attachment.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1786-1798"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}